Mucopolysaccharidosis Type I Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Mucopolysaccharidosis Type I pipeline constitutes 8+ key companies continuously working towards developing 8+ Mucopolysaccharidosis Type I treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Mucopolysaccharidosis Type I Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mucopolysaccharidosis Type I Market.

The Mucopolysaccharidosis Type I Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Mucopolysaccharidosis Type I Pipeline Report: https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Mucopolysaccharidosis Type I treatment therapies with a considerable amount of success over the years.
• Mucopolysaccharidosis Type I companies working in the treatment market are BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, and others, are developing therapies for the Mucopolysaccharidosis Type I treatment
• Emerging Mucopolysaccharidosis Type I therapies in the different phases of clinical trials are ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, ISP-001, JWK-008 Chengdu, RGX 111, SIG 005, Pentosan Polysulphate, JNS102, and others are expected to have a significant impact on the Mucopolysaccharidosis Type I market in the coming years.
• In December 2025, Anticipating an FDA decision on its Hunter syndrome therapy in April, Denali Therapeutics has secured a $275 million financing agreement with Royalty Pharma to support the potential launch of tividenofusp alfa and further development of its neurodegenerative disease pipeline. This funding follows a three-month delay in tividenofusp alfa's PDUFA date after Denali submitted updated clinical pharmacology data. The company's marketing application, based on a Phase I/II study, was granted priority review by the FDA in July 2025. Under the agreement, Royalty Pharma will provide an initial $200 million payment if the therapy receives accelerated FDA approval for Hunter syndrome (MPS II), with an additional $75 million payable upon EMA approval by the end of 2029.
• In June 2025, The European Commission (EC) has awarded orphan drug designation (ODD) to JR-446, an experimental therapy from Medipal and JCR Pharmaceuticals, for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also referred to as Sanfilippo syndrome type B.

Mucopolysaccharidosis Type I Overview
Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome, is a rare genetic disorder belonging to a group of diseases called mucopolysaccharidoses (MPS). These disorders are characterized by the body's inability to properly break down complex sugar molecules called glycosaminoglycans (GAGs), leading to their accumulation in various tissues and organs.

Get a Free Sample PDF Report to know more about Mucopolysaccharidosis Type I Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Mucopolysaccharidosis Type I Drugs Under Different Phases of Clinical Development Include:
• ALDURAZYME (laronidase): BioMarin Pharmaceutical/Sanofi
• OTL-203: Orchard Therapeutics/Kyowa Kirin
• Lepunafusp alfa (JR-171): JCR Pharmaceuticals
• RGX-111: REGENXBIO/Nippon Shinyaku
• ISP-001: Immusoft
• JWK-008 Chengdu: Genevector Biotechnology
• Research programme: oligonucleotide based RNA base editing therapeutics EdiGene Inc.
• RGX 111: REGENXBIO
• SIG 005: Sigilon Therapeutics
• Pentosan Polysulphate: Paradigm Biopharma
• JNS102: Jupiter Neurosciences

Route of Administration
Mucopolysaccharidosis Type I pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Mucopolysaccharidosis Type I Pipeline Therapeutics Assessment
• Mucopolysaccharidosis Type I Assessment by Product Type
• Mucopolysaccharidosis Type I By Stage and Product Type
• Mucopolysaccharidosis Type I Assessment by Route of Administration
• Mucopolysaccharidosis Type I By Stage and Route of Administration
• Mucopolysaccharidosis Type I Assessment by Molecule Type
• Mucopolysaccharidosis Type I by Stage and Molecule Type

DelveInsight's Mucopolysaccharidosis Type I Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Mucopolysaccharidosis Type I product details are provided in the report. Download the Mucopolysaccharidosis Type I pipeline report to learn more about the emerging Mucopolysaccharidosis Type I therapies
https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Mucopolysaccharidosis Type I Therapeutics Market include:
Key companies developing therapies for Mucopolysaccharidosis Type I are - Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., Paradigm Biopharmaceuticals Ltd., and others.

Mucopolysaccharidosis Type I Pipeline Analysis:
The Mucopolysaccharidosis Type I pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Mucopolysaccharidosis Type I with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mucopolysaccharidosis Type I Treatment.
• Mucopolysaccharidosis Type I key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Mucopolysaccharidosis Type I Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mucopolysaccharidosis Type I market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Mucopolysaccharidosis Type I drugs and therapies
https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Mucopolysaccharidosis Type I Pipeline Market Drivers
• Increase in prevalence of Mucopolysaccharidosis type I, further understanding in pathogenesis are some of the important factors that are fueling the Mucopolysaccharidosis Type I Market.

Mucopolysaccharidosis Type I Pipeline Market Barriers
• However, lack of awareness of signs and symptoms of the disorder, challenges in predicting disease severity in newborn screening and other factors are creating obstacles in the Mucopolysaccharidosis Type I Market growth.

Scope of Mucopolysaccharidosis Type I Pipeline Drug Insight
• Coverage: Global
• Key Mucopolysaccharidosis Type I Companies: BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, and others
• Key Mucopolysaccharidosis Type I Therapies: ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, ISP-001, JWK-008 Chengdu, RGX 111, SIG 005, Pentosan Polysulphate, JNS102, and others
• Mucopolysaccharidosis Type I Therapeutic Assessment: Mucopolysaccharidosis Type I current marketed and Mucopolysaccharidosis Type I emerging therapies
• Mucopolysaccharidosis Type I Market Dynamics: Mucopolysaccharidosis Type I market drivers and Mucopolysaccharidosis Type I market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.